Status:

TERMINATED

Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial

Lead Sponsor:

Indiana University

Collaborating Sponsors:

Vanderbilt University

Conditions:

Heart Failure

Heart Failure Acute

Eligibility:

All Genders

21+ years

Phase:

PHASE2

Brief Summary

Nearly 80% of acute heart failure (AHF) patients admitted to the hospital are initially treated in the emergency department (ED). Once admitted, within 30 days post-discharge, 27% of patients are re-h...

Detailed Description

The primary goal of the N-FURIOUS pilot trial is to determine whether a nitrate intense strategy safely reduces congestion, defined by LUS B-lines, better than a diuretic intense strategy. This pilot...

Eligibility Criteria

Inclusion

  • Age ≥ 21 years
  • Presents with shortness of breath at rest or with minimal exertion
  • Clinical diagnosis of AHF and presence of \> 15 total bilateral B-lines distributed in at least 4 zones on initial LUS
  • Hx of chronic HF and ANY ONE OF THE FOLLOWING:
  • \[Chest radiograph consistent with AHF
  • Jugular venous distension
  • Pulmonary rales on auscultation
  • Lower extremity edema
  • BNP \> 500pg/mL\]

Exclusion

  • Chronic renal dysfunction, including ESRD or eGFR \< 20 ml//min/1.73m2.
  • Shock of any kind. Any requirement for vasopressors or inotropes.
  • SBP \< 120
  • Need for immediate intubation
  • Acute Coronary Syndrome OR new ST-segment elevation/depression on EKG. (troponin release outside of ACS is allowed)
  • Fever \>101.5ºF
  • End stage HF: transplant list, ventricular assist device
  • Anemia requiring transfusion
  • Known interstitial lung disease
  • Suspected acute lung injury or acute respiratory distress syndrome (ARDS)
  • Pregnant or recently pregnant within the last 6 months
  • Severe valvular disease
  • Anuria
  • Allergy or hypersensitivity to nitroglycerin, furosemide or sulfa
  • Concern for cardiac tamponade or restrictive cardiomyopathy
  • Elevated intracranial pressure
  • Recent use of PDE5 inhibitors

Key Trial Info

Start Date :

December 14 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2021

Estimated Enrollment :

52 Patients enrolled

Trial Details

Trial ID

NCT03259165

Start Date

December 14 2017

End Date

December 31 2021

Last Update

August 20 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Eskenazi Health

Indianapolis, Indiana, United States, 46202

2

IU Health Methodist Hospital

Indianapolis, Indiana, United States, 46202

3

Vanderbilt University

Nashville, Tennessee, United States, 37235